托拉塞米和呋塞米治疗心肾综合征疗效对比分析

Comparative analysis of the efficacy of tolasemide and fursal in the treatment of cardiorenal syndrome

目的探讨托拉塞米和呋塞米治疗心肾综合征疗效。方法选取2017年2月~2019年2月100例心肾综合征患者为研究对象,将患者分为观察组与对照组,各50例。观察组采用托拉塞米治疗,对照组采用呋塞米治疗,对比两组临床疗效、临床指标变化情况及安全性。结果观察组患者的治疗有效率为96.00%,明显高于对照组的76.00%(P<0.05);观察组日平均尿量明显多于对照组,血钾水平明显高于对照组,体质量明显轻于对照组(P<0.05)。观察组患者的不良反应率为4.00%,明显低于对照组的18.00%(P<0.05)。结论针对心肾综合征患者,采用托拉塞米治疗取得的治疗效果显著优于呋塞米,且利尿效果显著,安全性高。

Objective To investigate the efficacy of tolasemide and furosemide in the treatment of cardiorenal syndrome. Methods 100 patients with cardiorenal syndrome were selected and divided into observation group and control group according to 1:1 ratio during the period from February 2017 to February 2019. The former was treated with torasemide and the latter was treated with furosemide. The clinical efficacy and changes of clinical indicators were compared between the two groups. Situation and safety. Results 96.00% of the patients in the observation group were effective,significantly higher than 76.00% in the control group( P < 0.05);the average daily urine volume in the observation group was significantly more than that in the control group,the blood potassium level was significantly higher than that in the control group,and the body weight was significantly lighter than that in the control group( P < 0.05). The adverse reaction rate of the observation group was 4.00%,which was significantly lower than that of the control group( 18.00%)( P < 0.05). Conclusion For patients with cardiorenal syndrome,tolasemide is superior to furosemide in the treatment of cardiorenal syndrome. It can stabilize the internal environment of patients,and has significant diuretic effect and high safety,which is worthy of continuous clinical promotion.